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Abstract
Background: suPAR biomarker generally considered a pathogenic factor in FSGS. However, studies have been
published that dispute this conclusion. The current study was designed to investigate the roles of uPA and suPAR
in FSGS in clinical and mouse models.
Methods: Clinical subjects including those with biopsy-proven FSGS and MCD were enrolled. To verify the role of
uPA in FSGS, Adriamycin was used to induce FSGS in uPA knockout (uPA−/−) and BALB/c (WT) mice. Proteinuria and
suPAR, the cleaved/intact forms of the circulating suPAR, and possible proteases involving cleavage of the suPAR
were also studied.
Results: FSGS clinical cases presented significantly higher serum levels of suPAR and Cr and lower serum levels
of uPA. In the mice model, the uPA−/− group exhibited faster disease progression and worsening proteinuria than
the WT group. In addition, the uPA−/− group had higher plasma suPAR levels, glomerular cell apoptosis, and
dysregulation of the Th1/Th2 balance. In an analysis of suPAR variants in FSGS, both the intact and cleaved forms of
the suPAR were higher in clinical subjects and the mouse model. However, the process of suPAR cleavage was not
mediated by enzymatic activities of the uPA, elastase, or cathepsin G.
Conclusions: A deficiency of uPA accelerated the progression of Adriamycin-induced mouse FSGS model. Decrease
of serum uPA levels may be an indicator of the progression of FSGS in clinical subjects and animal models.
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Background
Focal and segmental glomerulosclerosis (FSGS) accounts
for up to 20 % of glomerular disease and is a major
cause of end-stage renal disease (ESRD). The pathogen-
esis of FSGS and underlying causes remain unclear;
however, it was postulated that certain circulating factors
may be responsible for initiating renal injury [1]. In
2011, Wei et al. identified increased levels of the soluble
urokinase-type plasminogen activator (uPA) receptor
(suPAR) in approximately two-thirds of patients with
FSGS, and suPAR levels were predictive of FSGS recur-
rence in transplanted kidneys [2]. They suggested that
serum suPAR may be a circulating factor causing FSGS
[3]. In contrast, a cohort study by Meijers et al. did not
support use of the suPAR as a biomarker for FSGS [4],
and suggested that the currently available measurement
by suPAR assays had no proven clinical value in patients
with FSGS [5]. The role of the suPAR in the progression
of FSGS remains controversial.
The suPAR is derived from the uPAR, which is
expressed on the cell surface of multiple cell types, in-
cluding vascular endothelial cells and immune cells.
Cell-surface plasminogen activation is catalyzed by the
binding of the uPA and uPAR, which facilitates the bind-
ing of plasminogen to the cell surface, and controls fi-
brinolysis [6, 7]. In addition, the uPAR is also involved
in many other non-proteolytic biological processes, such
as cell migration, adhesion, angiogenesis, and cell
proliferation [8–10]. The primary structure of the ma-
ture uPAR is formed by approximately 90-amino-acid,
cysteine-rich LY6-like, short linker regions connecting
three homologous domains (D1, D2, and D3, numbered
from the N-terminus) that are linked to cell membranes
by glycosylphosphatidylinositol (GPI) [11, 12]. The uPAR
binds the uPA in a pocket comprising three extracellular
domains, while the entire external surface interacts with
other signaling molecules such as integrins, formyl pep-
tide receptors, and epithelial growth factor receptor, the
mannose-6-phosphate receptor, the family of low-density
lipoproteins receptor-related proteins, p130, and others
[13–15]. The GPI-anchored membranous uPAR can be
cleaved to various soluble forms of the uPAR (suPAR),
including glycolipid-anchored and soluble forms of the
intact uPAR D1 ~D3, and the cleaved receptor, uPAR
(D2 ~ D3) and uPAR (D1) [16, 17]. It was suggested that
the proteolytic cleavage of the uPAR between D1 and D2
depends on the binding of the uPA and plasmin [18].
suPAR levels in human body fluids are quite stable in
healthy individuals, while increased levels can be ob-
served in the plasma and serum with several disease
conditions, such as immunological disorders and cancers
[19–21]. Both intact and cleaved suPAR variants may
have diagnostic and prognostic values in cancer, inflam-
mation, and metabolic diseases; in addition, cleaved
forms of the suPAR were suggested to be stronger prog-
nostic markers for cancer diagnoses [22]. To the present,
the composition of different circulating suPAR variants
in FSGS patients has not been studied.
In general, it is thought that the suPAR scavenges the
uPA and prevents its interaction with the membrane-
anchored uPAR. However, since the circulating suPAR
can cause FSGS by activating the podocyte β3 integrin
downstream signaling pathway [2], there is an alternative
hypothesis in which the uPA may also work as a sca-
venger for the suPAR in FSGS. The present study was
designed to examine the role of the uPA in the patho-




Approval for the human subject study was granted
(TSGHIRB: 094-05-0031) by the institutional review board
of the Tri-service General Hospital (Taipei, Taiwan). Writ-
ten consent was taken from all participants to collect and
store the samples and to use medical outcome data for the
purpose of the study. All participants were over 20 years
old and capable of providing informed consent. Subjects
seen in the Tri-service General Hospital Renal Clinic were
included based on the results of a percutaneous renal
biopsy with a diagnosis of FSGS and of minimal-change
disease (MCD). Eighteen FSGS and 22 MCD patients were
enrolled in this study. Urine and blood samples were
obtained at the time of the renal biopsy. Samples were
stored at − 80 °C before being analyzed.
FSGS mice model
Healthy female Balb/c inbred mice (WT) 7 weeks of ages
were obtained from the National Laboratory Animal Breed-
ing and Research Center (Taipei, Taiwan). The uPA−/−
Balb/c mice (C.129S2-Plautm1Mlg/J) were originally pur-
chased from Jackson Laboratory (Bar Harbor, Maine,
USA), and bred in the animal center of National Defense
Medical Center. After arrival, the animals were randomly
allocated in groups of 6 in macrolon II cages. Animals
were kept in a controlled specific pathogen-free environ-
ment, fed standard rodent chow ad libitum, under a
12 h day/ 12 h night rhythm. The animals were allowed to
acclimatize for 1 week before starting the experimental
protocol and were monitored daily for general health. Age
(8 weeks) and body weight (~20 g) matched WT and
uPA−/− mice were intravenously treated with Adriamycin
at a dose of 10 mg/kg. At weekly intervals (W0 ~ 4),
indicated numbers of WT and uPA−/− mice were eutha-
nized (W0, n = 10; W1, n = 27; W2, n = 18; W3, n = 24;
W4, n = 11). Blood samples were collected into a 1.5-ml
microtube containing heparin through the retro-orbital
venous plexus, and were then centrifuged (at 2500 rpm
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for 15 min), and the supernatant containing the plasma
was withdrawn and stored at − 70 °C until for the follow-
ing study. Spot urine samples were collected at indicated
time point. The kidney tissues were obtained at the time
of euthanization.
The animal experiments were conducted according to
all applicable provisions of the Taiwan Animal Protection
Act of 1998. This study was approved by the Animal Ex-
perimentation Ethical Committee of the National Defense
Medical Center under permit number IACUC-13-017.
Enzyme-linked immunosorbent assay (ELISA)
Human serum levels of the suPAR were determined
using a Human uPAR Quantikine ELISA Kit (DUP00,
R&D, Minneapolis, MN) according to the manufacturer’s
protocol. Briefly, a capture antibody was pre-coated onto
microplate wells and incubated overnight at room tem-
perature (RT). Standards and samples were introduced
to the wells and incubated for 2 h at RT. After washing,
a biotinylated detection antibody was added to each well
and incubated for 2 h at RT, followed by the addition of
100 μL streptavidin horseradish peroxidase (HRP) and
incubation for 20 min at RT. A chromogen TMB sub-
strate solution was added to the wells and incubated for
30 min at RT. Fifty microliters of stop solution was
added to each well and read at 450 nm within 30 min.
The method for the mouse plasma suPAR was per-
formed according to the Mouse uPAR DuoSet (DY531,
R&D). Ten individual samples at indicated time points
were randomly selected for testing.
Western blotting
Protein concentration in the human serum/mouse
plasma samples was determined by the bicinchoninic
acid (BCA) assay (Pierce, Rockford, IL). Equal amounts
(30 μg) of protein from each samples were separated by
sodium dodecylsulfate polyacrylamide gel electrophor-
esis (SDS-PAGE). The gel was equilibrated in transfer
buffer at RT, and the protein was transferred onto poly-
vinylidene difluoride membranes (Millipore Immobilon-
P, Sigma, St. Louis, MO) for 2.5 h at 4 °C in transfer
buffer. The membranes were then blocked with 2 %
bovine serum albumin (BSA) of TBST at 4 °C overnight.
The next day, membranes were washed with TBST, and
blots were individually incubated with antibodies against
the human uPAR (MAB807, R&D) or mouse uPAR
(MAB531, R&D) overnight at 4 °C, followed by incuba-
tion with a goat anti-rabbit antibodyfor 30 min at RT.
Bindings were visualized with the Western Lightning
Chemiluminescence Reagent Plus (Perkin-Elmer Life
Sciences, Boston, MA) and exposed to Kodak film
(Rochester, NY). Five individual samples at indicated time
points were randomly selected for testing.
Evaluation of renal histopathology
Formalin-fixed and paraffin-embedded kidney tissues
were cut and stained with periodic acid-Schiff (PAS)
stain and colloidal iron for the general histological
examination as previously described [23]. Furthermore,
to evaluate the severity of glomerular injury, glomeruli
were examined using an Aperio digital microscope and
quantified with the Scanscope digital program [24]. The
developed tissues were counterstained with hematoxylin.
Sections were then observed with an optical photomi-
croscope. Negative controls were performed by omitting
the primary antibodies.
Measurement of the helper T-cell 1 (Th1)/Th2 immune
response
Mouse plasma concentrations of immunoglobulin G1
(IgG1), IgG2a, and IgG3 were measured using an ELISA
as previously described [25]. IgG1, IgG2a, and IgG3
mouse reference sera (mouse IgG1, IgG2a, and IgG3
quantitation kits; Enzo Life Sciences, Farmingdale, NY)
were used to construct a standard curve according to
the manufacturer’s instructions. Ten individual samples
at indicated time points were randomly selected for
testing.
Assay of cathepsin G and elastase activity
Elastase activity was detected as previously described
[26], 50 μl blood plasma was incubated at 37 °C for
24 h with 50 μl of 1 mM elastase substrate (M4765,
N-methoxy-succinyl-alanyl-alanyl-prolyl-valyl-p-nitroanilide,
Sigma). The absorbance was measured on a microplate
reader at 410 nm. The activity of cathepsin G was
evaluated by a Cathepsin G Activity Assay Kit (ab126780,
Abcam, Cambridge, MA), and all procedures were per-
formed according to the manufacturer’s instructions. Six
individual samples at indicated time points were randomly
selected for testing.
Statistical analysis
The statistical analysis of differences between groups
was performed by a t-test. Significance was defined as
p < 0.05. Pearson correlation coefficients were calculated
for normally distributed variables; otherwise Spearman
correlation coefficients were calculated. Data are ex-
pressed as the mean ± standard error (SE).
Results
FSGS patients showed higher suPAR and lower uPA levels
In this study, we first analyzed the demographic data,
basic biochemistry, and serum suPAR and uPA levels in
18 FSGS and 22 MCD patients. As shown in Table 1,
FSGS patients presented higher suPAR levels compared to
MCD patients (3.67 ± 0.17 vs. 2.03 ± 0.18 ng/ml; p < 0.05),
but significant lower levels of the uPA (0.1 ± 0.02 vs.
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0.44 ± 0.15 ng/ml; p < 0.05). In addition, human serum
suPAR levels showed a moderate correlation to serum
Cr levels in FSGS patients (r2 = 0.584, p < 0.0001) (Fig. 1).
There were no significant differences in plasma levels of
albumin or Up/Ucr between FSGS and MCD patients.
The data imply that increased suPAR and decreased uPA
levels could be indicators for FSGS, and there may be
important functions of uPA and suPAR in FSGS.
Deficiency of the uPA accelerated the progression of
FSGS in a mice model
To elucidate the role of the uPA in FSGS, we used
uPA−/− mice in an established FSGS mice model. FSGS in
this mice model was induced by an intravenous injection
of Adriamycin, and mice exhibited proteinuria and focal
sclerosis of glomeruli, which are similar to early patho-
logical features in FSGS human subjects. Compared to the
WT group, the uPA−/− group showed significant decreases
in renal functions, with earlier onset of worsening protein-
uria and hypoalbuminemia and faster deterioration (Fig. 2).
As for PAS staining of kidney tissues, the degree of glo-
merulosclerosis increased with progression of the disease
in both groups, and the severity in uPA−/− mice was sig-
nificantly higher than that in WT mice at W1 (Fig. 3a, b).
In the earlier stage of the progression (W1 and W2), ex-
pression of glomerular polyanions in the uPA−/− group
was also significantly lower compared to that of the WT
group (Fig. 3c). In addition, uPA−/− mice also showed an
increase in glomerular cell apoptosis at W2 and W3
(Fig. 3d). This evidence indicates that in addition to exac-
erbated renal dysfunction, uPA−/− mice showed acceler-
ated destruction of the glomerular structural integrity due
to increased glomerular cell apoptosis.
Differential subsets of helper T cells were proposed to
be involved in the pathogenesis of glomerular nephritis.
Th1-predominant immune responses are strongly asso-
ciated with proliferative and crescentic forms of GN,
while Th2 responses are associated with membranous
patterns of injury [27]. Th1 and Th2 cells can antagonize
each other’s actions, suggesting that certain strategies in
modulating the Th1/Th2 balance may influence the dis-
ease severity. The Th1/Th2 balance takes into consider-
ation both Th1 IgG2a and IgG3 subclasses compared to
the Th2 IgG1 subclass. The ratio of IgG1/IgG2a + IgG3
was significantly increased in the WT group from W1,
but there was no change in the uPA−/− group (Fig. 4),
suggesting that uPA−/− mice fail to generate a type 2 im-
mune response which may contribute to acceleration of
Adriamycin-induced FSGS.
Both the intact and cleaved forms of the suPAR were
higher in FSGS, and the uPA, elastase, and cathepsin G
were not involved in the cleavage process
As mentioned earlier, there may be an interaction be-
tween uPA and suPAR levels in the progression of FSGS.
Before the induction of FSGS, there was no difference in
plasma suPAR levels between the WT and uPA−/−
groups. In the FSGS model, suPAR levels gradually in-
creased after induction and reached the highest level at
W2 in the WT group, while uPA−/− mice presented the
highest suPAR levels at W1. In addition, compared to
the WT group, plasma suPAR levels all increased at
different time points in the uPA−/− group (Fig. 5a). The
anti-uPAR antibody used herein was generated by Leu24-
Thr297 of the uPAR, and therefore can be applied to dis-
criminate the intact form(s) of the suPAR (D1D2D31–277)
and cleaved form(s) (D2D384–274) by a Western blot ana-
lysis. As shown in Fig. 5b, two different groups of detected
bands were noted: one was around 55 kDa, the other
was <55 kDa, which are respectively denoted as the
intact and cleaved forms. The presence of cleaved
suPAR forms increased in both groups compared to
Table 1 Biochemical and serologic features of clinical subjects
Subject Age (years) Gender suPAR (ng/ml) uPA (ng/ml) Creatinine (mg/dl) Up/UCr
MCD 36.00 ± 4.25 3 F/19 M 2.03 ± 0.18 0.44 ± 0.15 1.13 ± 0.26 7.7 ± 0.03
FSGS 56.83 ± 8.29 4 F/14 M 3.67 ± 0.17* 0.1 ± 0.02* 3.42 ± 1.41* 8.92 ± 4.12
uPA urokinase-type plasminogen activator, suPAR soluble uPA receptor. * p<0.05 vs. MCD
Fig. 1 Moderate correlation between human plasma soluble
urokinase-type plasminogen activator (uPA) receptor (suPAR) and
serum creatinine in combination of FSGS (red) and MCD (blue)
clinical cases
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Fig. 2 Deficiency of the urokinase-type plasminogen activator (uPA) accelerated the decrease of renal functions in a focal segmental glomerulosclerosis
(FSGS) mouse model. a Proteinuria was expressed as total protein (mg/ml) over creatinine (mg/dl), and (b) plasma albumin was determined in
wild-type (WT) and uPA−/− groups during the course of the experiment until 4 weeks after Adriamycin treatment. #p < 0.05 vs. week 0 (W0);
*p < 0.05 vs. the WT
Fig. 3 Deficiency of the urokinase-type plasminogen activator (uPA) exacerbated the severity of renal histopathological changes in a focal segmental
glomerulosclerosis (FSGS) mouse model. At the end of the experiment, kidney samples were collected for a histopathological examination.
a Representative sections from renal tissue in wild-type (WT) and uPA−/− groups were evaluated with PAS staining (lines 1 and 2), colloidal iron staining
(lines 3 and 4), and TUNEL staining (lines 5 and 6), at an original magnification of 400x. Semi-quantification analyses of PAS (b), colloidal iron (c), and
TUNEL (d) staining are also presented. #p < 0.05 vs. week 0 (W0); *p < 0.05 vs. the WT
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levels before induction. However, there was no signifi-
cant difference between the WT and uPA−/− groups,
suggesting that cleavage of the suPAR is independent
of the uPA. In addition, we further examined the
composition of intact and cleaved forms of the suPAR
in clinical subjects, and an increase in the cleaved-
form of the suPAR was also found in FSGS (Fig. 6).
According to the data, the cleaved forms increased in
the FSGS animal model and clinical subjects, suggest-
ing that the increase in cleaved forms of the suPAR
may also play a role in FSGS.
It was reported that the secretable cationic neutral
serine proteases, elastase and cathepsin G, can cleave
the uPAR and regulate its functions [28]. We further
examined the activities of these two proteinases in the
FSGS mice model. In the progression of FSGS, elastase
activity had increased at W3, while cathepsin G activity
reached its highest level at W1 (Fig. 7). However, activ-
ities of both elastase and cathepsin G in the uPA−/−
group were lower than those in the WT group, in-
dicating that these two proteases did not participate in
cleaving the suPAR in FSGS.
Discussion
The meaning of circulating suPAR levels in FSGS is still
under debate. In two different ethnic cohorts of primary
FSGS, serum suPAR levels were elevated in 84.3 and
55.3 % of FSGS patients, while only in about 6 % of con-
trol subjects. Treatment with mycophenolate mofetil
and reduction of proteinuria were both associated with a
reduction in suPAR, and gave higher odds for complete
remission in a clinical trial study [3]. Furthermore,
evidence has been reported that NPHS2 mutations were
detected in 45 % ~ 55 % of families and 8 % ~ 20 % of
patients with sporadic nephrotic syndrome [29]. FSGS
patients with an NPHS2 mutation also presented higher
suPAR levels than those without a mutation [3]. How-
ever, recent studies suggested that eGFR is a potent
determinant of suPAR levels [4, 30] and that an absolute,
eGFR-independent, suPAR concentration cutoff (3.0 ng/ml)
could not successfully be determined for FSGS patients
[4]. In addition, Sinha et al. reported that suPAR levels
could not identify FSGS among other causes of nephrotic
syndrome in children [30]. In another study, suPAR levels
were increased, but researchers were unable to distinguish
primary from secondary FSGS [31]. In the current study,
FSGS patients had higher suPAR levels (3.67 ± 0.17 ng/ml)
compared to MCD patients (2.13 ± 0.18 ng/ml) and serum
suPAR levels showed a moderate correlation to serum Cr
levels in FSGS patients. Furthermore, suPAR levels were
significantly higher at W1 after Adriamycin treatment and
stayed elevated throughout the study. The uPA-deficient
mice model showed higher suPAR levels and faster disease
progression than WT mice. These data indicate that
suPAR levels can be used to evaluate the disease in both
clinical subjects and an animal model of FSGS.
It is of note that, in addition to FSGS, increased con-
centration of suPAR has been observed in different
glomerular diseases. In a recent study, we also found
serum suPAR was elevated in most kidney diseases, such
as diabetic nephropathy [32], but not MCD. Zhao et al.
also reported plasma suPAR levels of patients with IgA
nephropathy (IgAN) were significantly lower than those
in patients with primary FSGS, and higher than those
with MN, MCD and healthy controls. In IgAN patients,
plasma suPAR levels were positively associated with
proteinuria and negatively associated with eGFR [33].
Although serum suPAR levels had some diagnostic value
in FSGS, a more precise determinant cut-off value and
suPAR combinations with other biomarkers are still
needed.
Although use of suPAR as a diagnosis tool is under de-
bate, it is certainly a factor in the pathogenesis of FSGS.
The current methodology of determining suPAR levels
might not be able to reliably distinguish FSGS from
other proteinuric glomerular diseases [34]. It has been
suggested that variants of the suPAR may also have diag-
nostic and prognostic values [22], which may be another
indicator for an FSGS diagnosis. Herein, we performed a
WB analysis to differentiate the suPAR variants in both
animal models and clinical subjects. As shown in Fig. 5,
the cleaved form increased in the FSGS animal model
after induction. Both the intact and cleaved forms
increased in clinical subjects, but this process was not
mediated by uPA, elastase, or cathepsin G. Wei et al., re-
ported circulating suPAR regulated kidney permeability
Fig. 4 Urokinase-type plasminogen activator (uPA)-deficient mice
failed to generate a type 2 immune response in a focal segmental
glomerulosclerosis (FSGS) mouse model. Plasma samples in the
wild-type (WT) and uPA−/− groups were collected at indicated time
points to determine levels of immunoglobulin G1 (IgG1), IgG2a, and
IgG3. Data are presented as the ratio of IgG1 over the combination
of IgG2a and IgG3. #p < 0.05 vs. week 0 (W0); *p < 0.05 vs. the WT
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via β3 integrin down-stream signaling in podocytes, pro-
moting cell motility and activation of the small GTPases
Cdc42 and Rac1 [35]. However, which fractions of
suPAR mediated the activation of β3 integrin remains
unclear. In a recently study, Alfano et al., provided in
vitro evidence that full-length suPAR but not cleaved
suPAR variant has the capability to induce nephrin
down-regulation in human podocytes [36]. The detailed
mechanisms and functions of increased cleavage in
suPAR variants in FSGS still need further investigation.
Although it is still too early to draw conclusions about
suPAR variants in an FSGS diagnosis, we hope to have
additional information after further studies. In addition
to serum suPAR levels for an FSGS diagnosis, it was
reported that the urinary suPAR is elevated and
Fig. 5 Plasma soluble urokinase-type plasminogen activator (uPA) receptor (suPAR) levels and expression patterns in a focal segmental glomerulosclerosis
(FSGS) mouse model. a Plasma suPAR levels were determined in the wild-type (WT) and uPA−/− groups during the course of the experiment until 4 weeks
after Adriamycin treatment. b Immunoblot analysis of the expression of plasma suPAR variants in the WT (upper panel) and uPA−/− (lower panel) groups
at the indicated time points are presented. #p < 0.05 vs. week 0 (W0); *p < 0.05 vs. the WT
Fig. 6 Expression patterns of soluble urokinase-type plasminogen
activator receptor (suPAR) variants in clinical subjects. Immunoblot
analyses of expressions of serum suPAR variants in minimal-change
disease (MCD) and focal segmental glomerulosclerosis (FSGS) clinical
subjects are presented
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pathogenic in patients with primary FSGS [37] and may
be used to identify cases of recurrent FSGS in kidney
transplant candidates [38].
Expansion of the extracellular matrix (ECM) might
not only result from increased matrix protein synthesis
by fibroblasts but also from decreased degradation by
proteases such as metalloproteinases and serine prote-
ases. Actually, uPA is considered to be a logical source
of endogenous renal antifibrotic activity through enhan-
cing the process of protein degradation [39]. In addition,
uPA has been reported to have the ability to promote
tissue repair through activation of growth factors, such
as hepatocyte growth factor (HGF) [40, 41]. Stimulation of
podocytes with HGF in vitro resulted in antiapoptotic
phosphorylation of AKT and extracellular signal-regulated
kinase and induction of the X-linked inhibitor of apoptosis
protein. In the same study, diminution of the HGF down-
stream signaling pathway in podocytes contributes to cell
loss and FSGS in transplant glomerulopathy [42]. How-
ever, evidence from uPA and uPAR deficient animals has
shown other molecules, such as vitronectin and high mo-
lecular weight kininogen, are alternate uPAR ligands, and
receptors in addition to uPAR may also bind directly to
uPA and activate cell signaling pathways [43]. In a renal
interstitial fibrosis obstructive nephropathy model (UUO)
[44], uPAR deficiency suppressed renal macrophage
recruitment but exacerbated the fibrogenic response,
which may partly have occurred through the delayed
clearance of angiogenic/profibrotic molecules and de-
creased receptor-associated uPA activity. In addition, the
number of apoptotic tubulointerstitial cells was also sig-
nificantly increased in uPAR deficient mice [45]. In con-
trast, Yamaguchi I et al., found uPA deficiency had no role
in the inhibition of interstitial fibrosis in the UUO model,
and suggested an organ-specific difference in basic
fibrogenic pathways [39]. Treatment with recombinant
suPAR to uPAR-knockout mice with 20 μg and greater led
to albuminuria within 24 h. In addition, sustained
overexpression of suPAR in the blood of WT mice leads
to an FSGS-like glomerulopathy [2]. Here, we used an
Adriamycin-induced FSGS model in uPA- knockout mice
to elucidate the role of uPA in FSGS. In the mice model of
our current study, uPA deficient accelerated Adriamycin-
induced FSGS in the early stage, but did not increase the
severity in the late stage (Fig. 3). This evidence suggests
uPA may play only a partial role in ameliorating ECM
expansion in the initial stage of FSGS.
It has been claimed that the pathogenesis of FSGS is
mainly mediated by the podocyte damage and loss. This
pathological process includes dysregulated slit diaphragm,
cytoskeleton, glomerular basement membrane, and af-
fected negative surface charge of the podocyte. An injured
podocyte will trigger cell apoptosis and detachment from
glomerular basement membrane, loss of glomerular struc-
tural integrity and result in sclerosis and scarring of the
glomerulus [46]. In the current study, we observed that
the increase of glomerular apoptotic cells and lower glom-
erular polyanions in uPA- deficient mice might imply an
anti-apoptotic role of uPA in the pathogenesis of FSGS
(Fig. 3). The underlying mechanisms may be mediated
through the activation of caspase-mediated apoptosis and
inhibit the PI3K/AKT pathway [47]. In addition, uPA has
been suggested as a major determinant of the basal level
of activated ERK/MAP kinase, and may prevent cell
apoptosis [48]. However, it has been reported that uPA
increases survival or pro-apoptotic signals in human
mesangial cells depending on the apoptotic stimulus [49].
The detailed mechanisms of uPA anti-apoptotic activity
still need further investigation.
The immunological mechanisms involved in the patho-
genesis of FSGS are unclear, but evidence suggests an asso-
ciation between Th2-polarization and disease development
[50]. For example, Yap et al. reported a correlation between
childhood idiopathic nephrotic syndrome and increased
IL-13 mRNA expression. In Buffalo/Mna spontaneously
developed FSGS rat model, a predominantly Th2 mRNA
Fig. 7 Neither elastase nor cathepsin G mediated cleavage of the soluble urokinase-type plasminogen activator (uPA) receptor (suPAR) in a focal
segmental glomerulosclerosis (FSGS) mouse model. Plasma activities of elastase (a) and cathepsin G (b) were determined in the wild-type (WT)
and uPA−/− groups during the course of the experiment until 4 weeks after Adriamycin treatment. #p < 0.05 vs. week 0 (W0); *p < 0.05 vs. the WT
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profile and the down-regulation of Th1 cytokine mRNA
was also observed [51]. It is known Th1 and Th2 cells can
provide B-cell help, and their signature cytokines IFN-γ
and IL-4 induce class switch recombination to IgG2a and
IgG3 or IgG1 and IgE, respectively [52]. In our study, uPA-
deficient animals didn’t switch to IgG2a and IgG3, but the
progression of FSGS was still accelerated. This indicates
the role of Th2 polarization maybe less important than a
uPA deficiency in the mice model of FSGS induced by
Adriamycin. At present, we are the first group to present
the idea and possible hypothesis of the role of Th2
polarization in the development of FSGS which may be
only applicable in certain models or conditions and not a
general effect.
Conclusion
In summary, we found that the increase in suPAR and
decrease in uPA levels both occurred in FSGS clinical
subjects. A gradual increase in suPAR levels was also
present in a mouse model of Adriamycin-induced FSGS.
In addition, disruption of uPA accelerated the onset of
FSGS and exacerbated its severity in proteinuria and cell
apoptosis. Dysregulation of the Th1/Th2 balance may
also be involved in uPA-regulated disease progression. In
addition, the suPAR in FSGS animals was manifested in
the cleaved form, while it was predominantly in the
intact form in control animals, and the cleavage process
was not mediated by the uPA, elastase, or cathepsin G
through an enzymatic process. These data suggest the
levels of serum uPA may be an indicator for the progres-
sion of FSGS in clinical subjects and animal models.
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